Jump to content

Suresh K. Alahari

Add links
From Wikipedia, the free encyclopedia
(Redirected from Draft:Suresh K. Alahari)
Suresh K. Alahari
Alma materDrexel University, Philadelphia, Ph.D. (Molecular Biology)
Occupation(s)Professor, cancer biologist, and molecular biologist
Websitelsuhsc.edu

Suresh K. Alahari is an American cancer biologist and molecular biologist.His primary focus is on research for cancer biology, particularly in breast cancer research.[1][2] He is a professor at Louisiana State University Health Sciences Center (LSUHSC) School of Medicine.[3][4] He has been recognized as a fellow of the American Association for the Advancement of Science and the American Society of Cell Biology.[5]

Biography

[edit]

Early life and education

[edit]

Alahari was born in India. He received his bachelor of science in Biology in 1983 from Andhra University, India, in 1983, followed by a master of science in Human Genetics in 1986. He completed his Ph.D. in Molecular Biology from Drexel University in Philadelphia in 1994.[5][6][7] During his doctoral research, he discovered a protein, prp4, that plays a significant role in pre-microRNA splicing.

Career

[edit]

After completing his Ph.D. in 1994, Alahari started a postdoctoral fellowship at the University of North Carolina[8][9][10] at Chapel Hill from 1994 to 1998, focusing on cancer biology, studying the mechanisms of tumor suppression and the roles of various proteins in cell signaling pathways.[5][11][12][13]

In 1998, Alahari joined the University of North Carolina faculty, where he continued his research on cancer biology. He contributed by discovering the protein Nischarin, vital in inhibiting cell migration and invasion in breast cancer.[12][3] His work demonstrated that Nischarin is a tumor suppressor, providing insights into potential therapeutic targets for breast cancer treatment.[11][7][14] Alahari published several papers on Nischarin, microRNAs, and small-molecule drugs.

In 2004, Alahari started working at the Louisiana State University Health Science Center (LSUSHC) in New Orleans. He joined as an associate professor and was later promoted to full professor. He has served as the Fred Brazda Professor of Biochemistry and Molecular Biology at LSUSHC, where he continues to lead research projects focused on cancer biology and therapeutic development.[15][10][11][16][17]

In addition, he served visiting professorships at the University of Pennsylvania, Philadelphia, and Rockefeller University, New York. Dr. Alahari is on the editorial boards of several journals, including Molecular Cancer, Oncogene, Journal of Biological Chemistry, Non-Coding RNA, Frontiers in Cell and Developmental Biology, Frontiers in Genetics, and International Journal of Human Genetics. In 2020, he won President's Gold Volunteer Award, American Society of Cell Biology (2020)[1]

Selected publications

[edit]
  • Shenouda, S.K., Alahari, S.K. MicroRNA function in cancer: oncogene or a tumor suppressor?. Cancer Metastasis Rev 28, 369–378 (2009). https://doi.org/10.1007/s10555-009-9188-5
  • A. E. Aplin, A. Howe, S. K. Alahari and R. L. Juliano, Signal Transduction and Signal Modulation by Cell Adhesion Receptors: The Role of Integrins, Cadherins, Immunoglobulin-Cell Adhesion Molecules, and Selectins, Pharmacological Reviews June 1, 1998, 50 (2) 197-264;
  • Mashouri, L., Yousefi, H., Aref, A.R. et al. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer 18, 75 (2019). https://doi.org/10.1186/s12943-019-0991-5
  • Alan Howe, Andrew E Aplin, Suresh K Alahari, RL Juliano, Integrin signaling and cell growth control, Current Opinion in Cell Biology, Volume 10, Issue 2, 1998, Pages 220-231, ISSN 0955-0674, https://doi.org/10.1016/S0955-0674(98)80144-0.
  • Serrano-Gomez, S.J., Maziveyi, M. & Alahari, S.K. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer 15, 18 (2016). https://doi.org/10.1186/s12943-016-0502-x
  • Baranwal, S. and Alahari, S.K. (2010), miRNA control of tumor cell invasion and metastasis. Int. J. Cancer, 126: 1283-1290. https://doi.org/10.1002/ijc.25014
  • Nischarin inhibits Rac induced migration and invasion of epithelial cells by affecting signaling cascades involving PAK[11][16]
  • The integrin-binding protein Nischarin regulates cell migration by inhibiting PAK[3][4]

Memberships

[edit]
  • American Association for Cancer Research
  • Indian Immunology Society
  • American Society of Pharmacology and Experimental Therapeutics
  • American Society for Cell Biology[5]
  • American Society of Biochemistry and Molecular Biology
  • American Academy for the Advancement of Sciences[12][13]
  • Sigma Xi Honors Society (2024-Present)

References

[edit]
  1. ^ a b Mullin, Emily (2013-01-29). "LSUHSC research provides new drug target for Her-2 related breast cancer". Fierce Biotech. Retrieved 2024-11-14.
  2. ^ "Study details exactly how Her2 gene promotes progression and spread of breast cancer cells". News-Medical. 2013-01-23. Retrieved 2024-11-14.
  3. ^ a b c Palermo, Jeff. "LSU research finds link between diabetes medicine, lower cancer rates". louisianaradionetwork.com. Retrieved 2024-11-14.
  4. ^ a b "Novel drug target for triple-negative breast cancer discovered". News-Medical. 2022-10-17. Retrieved 2024-11-14.
  5. ^ a b c d Woodruff, Emily (2019-09-22). "LSU researcher looking at 'miracle drug' metformin as potential weapon against breast cancer". NOLA.com. Retrieved 2024-11-13.
  6. ^ "LSU Health NO Discovery May Be Key to Obesity, Diabetes Rx | Healthcare Journal of New Orleans". www.healthcarejournalno.com. Retrieved 2024-11-14.
  7. ^ a b "Research: Metformin may be effective in treating breast cancer that lacks Nischarin protein". News-Medical. 2019-09-20. Retrieved 2024-11-14.
  8. ^ "MicroRNA could be used as a target in breast cancer research". Drug Target Review. Retrieved 2024-11-14.
  9. ^ special.to (2022-10-17). "LSU HEALTH RESEARCH FINDS NEW DRUG TARGET FOR TRIPLE-NEGATIVE BREAST CANCER". L'Observateur. Retrieved 2024-11-14.
  10. ^ a b Sreeraman, VR (2009-08-23). "New Targets for Treatment of Invasive Breast Cancer Identified". Med India. Retrieved 2024-11-14.
  11. ^ a b c d reports, Staff (2020-12-09). "LSU cancer researcher recognized, and other metro area health news". NOLA.com. Retrieved 2024-11-14.
  12. ^ a b c Post Staff, The ASCO (2021-01-25). "AAAS Announces Leading Scientists Elected as 2020 Fellows". ascopost.com. Retrieved 2024-11-14.
  13. ^ a b "AAAS Announces Leading Scientists Elected as 2020 Fellows | American Association for the Advancement of Science (AAAS)". www.aaas.org. Retrieved 2024-11-14.
  14. ^ "Novel drug target for triple-negative breast cancer discovered". News-Medical. 2022-10-17. Retrieved 2024-11-14.
  15. ^ "LSU Health NO Discovery May Be Key to Obesity, Diabetes Rx | Healthcare Journal of New Orleans". www.healthcarejournalno.com. Retrieved 2024-11-14.
  16. ^ a b "Study details exactly how Her2 gene promotes progression and spread of breast cancer cells". News-Medical. 2013-01-23. Retrieved 2024-11-14.
  17. ^ "Now, a novel research to advance cancer therapy". Big News Network.com. Retrieved 2024-11-14.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Suresh_K._Alahari&oldid=1257607059"